PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Missing Medicare data alters hospital penalties, study finds

Hospitals in areas with high Medicare Advantage enrollment face inflated financial penalties for readmissions, because government uses only traditional Medicare data

2026-01-22
(Press-News.org) For more than a decade, hospitals have worked to help older adults avoid repeated inpatient stays, incentivized by a federal program that cuts Medicare reimbursements if hospitals have higher-than-expected rates of readmissions for people with certain conditions.

The Hospital Readmissions Reduction Program has helped spur innovation, including initiatives to better prepare patients and their families to manage care after hospitalization, and to support them virtually at home.

But a new University of Michigan study finds that these financial penalties have hit some hospitals harder than they should, even if those hospitals have done a reasonable job at keeping people with heart failure, pneumonia and other serious conditions from ending up back in a hospital within a month of leaving one.

Such hospitals have been paying inflated readmission penalties for a seemingly unrelated reason: They happen to serve higher percentages of older adults who have chosen to enroll in Medicare Advantage plans run by private insurance companies.

So what’s the connection?

Currently, the federal government only grades hospitals on their readmission performance for older adults with traditional Medicare, which is run by the federal government. Data from Medicare Advantage are not currently included in the calculations that determine these penalties.

This is a problem, because Medicare Advantage enrollees tend to be healthier than traditional Medicare beneficiaries. But the readmission penalty program’s risk-adjustment is unable to capture these differences.

So, the researchers find, hospital performance looks worse for hospitals treating fewer traditional Medicare beneficiaries and more Medicare Advantage enrollees, even if those hospitals take the same actions to prevent readmissions as other hospitals.

The study, published in JAMA Network Open, suggests that not incorporating Medicare Advantage data results in an unwarranted redistribution of nearly $300 million a year in readmission penalties across hospitals nationwide. That’s more than half the total amount of readmissions penalties incurred each year across all hospitals.

Penalties are publicly reported every year and covered by the news media.

The Centers for Medicare and Medicaid Services has issued a rule to begin using Medicare Advantage data in the program. But even when it takes effect later this year, it will not affect hospital penalties for several years.

An unintended consequence with major consequences

The analysis shows an unintended consequence of the intersection between two major health policies of the last 15 years: the rapid rise in Medicare plan enrollment, and the HRRP, says senior author Geoffrey Hoffman, Ph.D., a professor at the U-M School of Nursing and member of the U-M Institute for Healthcare Policy and Innovation.

“Medicare Advantage has experienced extraordinary growth in the past decade, yet policymakers haven’t caught up with implications of this growth for Medicare payment policy that is based purely on traditional Medicare enrollment,” says Hoffman. “The omission of Medicare Advantage data highlights the continuing issue of inadequate measurement of patient risk in the Hospital Readmission Reduction Program, with important implications for the penalties that hospitals face.”

When the HRRP started calculating readmission rates in 2012, only 29% of older adults and people with disabilities chose Medicare Advantage plans.

Today, it’s 54%. But the distribution is not even across the country.

Hoffman and lead author Zoey Chopra, M.A., mapped that distribution and divided more than 3,200 hospitals into five groups based on the MA enrollment levels in 1,486 counties.

Chopra is working toward both a medical degree in the U-M Medical School and a Ph.D. in economics in the U-M College of Literature, Science and the Arts. He is a Medical Scientist Training Program fellow at the Medical School.

Differences in hospitals and populations

The hospitals in the areas with the highest Medicare Advantage enrollment were much more likely to be larger, nonprofit, teaching-oriented and in urban areas than hospitals in the areas with the lowest levels of Medicare Advantage enrollment.

Even when the researchers took into account an aspect of the readmission penalty program that only judges hospitals against groups of their peer hospitals, they still found that the Medicare Advantage enrollment rate mattered.

Past studies have shown that older adults who choose Medicare Advantage plans tend to be in the younger age range of eligibility, and to have fewer serious health conditions.

Hoffman has studied patterns of migration back to traditional Medicare by adults who had previously chosen Medicare Advantage plans, and factors that cause older adults to leave a Medicare Advantage plan for another Medicare Advantage plan or traditional Medicare.

Even though the readmission penalty program adjusts penalties based on the health risks of hospitals’ patients with the conditions that are included in the program, the lack of Medicare Advantage data could be a source of bias, he said.

Areas with more Medicare Advantage enrollees may end up with higher-risk traditional Medicare beneficiaries, because healthier enrollees migrate to Medicare Advantage. But those risk differences can’t be captured in the data models used by CMS. Therefore, by basing the program’s penalties only on traditional Medicare enrollees, hospitals with more Medicare Advantage patients are at greater, unwarranted risk of readmission penalties.

“Our study observes an inadvertent consequence of restricting the readmissions program to traditional Medicare participants,” said Chopra. “At the time of the HRRP’s rollout, this made sense, given lower enrollment and concerns about accuracy of the Medicare Advantage data. However, including Medicare Advantage data now appears imperative to avoid unnecessary penalties for hospitals treating relatively more private pay patients.”

Potential solutions

The new policy taking effect later this year rule will add Medicare Advantage data to HRRP calculations of readmissions, but Hoffman and Chopra have concerns about the completeness of what may be available. Risk-coding and policy differences across Medicare Advantage and traditional Medicare could also complicate comparisons of hospital performance.

It will also base penalties on the last two years’ worth of readmission data, instead of three. While the inclusion of Medicare Advantage data nearly doubles the amount of data used for comparisons, given concerns about data completeness and accuracy, this change may nonetheless make it harder statistically to see how hospitals have really done on keeping readmissions as low as possible, Hoffman said.

In addition to the rule, they suggest, CMS could consider factoring the percentage of Medicare Advantage enrollees in a hospital’s area or patient base into the calculations for its readmission rate and potential penalty.

The study was funded by the National Institute on Aging of the National Institutes of Health (RO1AG074944, T32AG000221). Chopra’s funding is through the Population Studies Center at the U-M Institute for Social Research. Andrew Ryan, Ph.D., of Brown University is a co-author of the study.

Hospital Readmission Reduction Program Penalties for Hospitals with High Medicare Advantage Penetration, JAMA Network Open, DOI:10.1001/jamanetworkopen.2025.54972

END


ELSE PRESS RELEASES FROM THIS DATE:

Experimental therapy targets cancer’s bodyguards, turning foe to friend to eliminate tumors

2026-01-22
[New York, NY [January 22, 2026]—Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them. The study, published in the January 22 online issue of Cancer Cell, a Cell Press Journal [DOI 10.1016/j.ccell.2025.12.021], was conducted in aggressive preclinical models of metastatic ovarian and lung cancer. It points to a new strategy ...

Discovery illuminates how inflammatory bowel disease promotes colorectal cancer

2026-01-22
A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a preclinical study by Weill Cornell Medicine investigators. The findings point to new possibilities for diagnosis, monitoring and treatment. The study began with a focus on TL1A, an inflammatory immune signaling protein known to be associated with IBD and colorectal cancer. Experimental drugs that block TL1A activity have shown great promise against IBD in clinical trials, but how the signaling ...

Quality and quantity? The clinical significance of myosteatosis in various liver diseases

2026-01-22
Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases. However, the field faces significant challenges, including a lack of standardized assessment methods, definitions, and diagnostic criteria, as well as an incomplete understanding of its pathophysiological mechanisms. This narrative review aims to synthesize current knowledge on myosteatosis in liver disease, covering its assessment, clinical impact across various etiologies, proposed ...

Expert consensus on clinical applications of fecal microbiota transplantation for chronic liver disease (2025 edition)

2026-01-22
The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases. To assist clinicians in rapidly mastering and standardizing the clinical application of FMT for chronic liver disease, the Liver-Related Digestive Diseases Group of the Chinese Society of Hepatology, Chinese Medical Association, has developed this expert consensus. The consensus comprehensively addresses key aspects of FMT application, including indications, contraindications, efficacy, safety, donor selection ...

Insilico Medicine to present three abstracts at the 2026 Crohn’s & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411, a novel gut-restricted PHD1/2 inhibitor fo

2026-01-22
Presentations include first-in-human Phase 1 results in healthy volunteers, 13-week repeat-dose toxicology in two species, and disease mitigation in a chronic T cell transfer-induced colitis model CAMBRIDGE, Mass. and SHANGHAI — January 22, 2026 — Insilico Medicine (“Insilico”, HKEX: 03696), a clinical-stage AI-driven biotechnology company, today announced it will present three abstracts at the 2026 Crohn’s & Colitis Congress 2026 in Las Vegas, USA on January 23, 2026 featuring new data supporting the continued development of ISM5411 (also referenced as ISM012-042), an orally administered, gut-restricted small-molecule ...

New imaging technology detects early signs of heart disease through the skin

2026-01-22
Researchers from Helmholtz Munich and the Technical University of Munich (TUM) have developed “fast-RSOM”, a new imaging technology that can capture detailed images of the smallest blood vessels directly through the skin – without the need for invasive procedures. By revealing early signs of cardiovascular risk, this technology could help doctors intervene sooner, guide personalized therapies, and improve long-term heart health. A New Window Into Microvascular Health One of the earliest warning signs of cardiovascular disease ...

Resurrected ancient enzyme offers new window into early Earth and the search for life beyond it

2026-01-22
By resurrecting a 3.2-billion-year-old enzyme and studying it inside living microbes, researchers at the University of Wisconsin–Madison have created a new way to improve our understanding of the origins of life on Earth and possibly recognize signs of life elsewhere. Recently published in Nature Communications, the NASA-funded study uses synthetic biology to reverse-engineer modern enzymes and rebuild their possible ancestors. Betül Kaçar, a professor of bacteriology, and Holly Rucker, a PhD candidate in Kaçar’s lab, focused on an enzyme called nitrogenase, which is critical to the process that converts atmospheric nitrogen into a form usable by living ...

People with obesity may have a higher risk of dementia

2026-01-22
WASHINGTON—People with obesity and high blood pressure may face a higher risk of dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Dementia is a growing global public health challenge, with no cure currently available. People with dementia experience a severe decline in mental abilities, like memory, thinking and reasoning. The most common forms of dementia are Alzheimer's disease, vascular dementia and mixed dementia. Dementia is a progressive brain ...

Insilico Medicine launches science MMAI gym to train frontier LLMs into pharmaceutical-grade scientific engines

2026-01-22
New “AI GYM for Science” dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10x performance gains on key drug discovery benchmarks and advancing the company’s vision of Pharmaceutical Superintelligence (PSI). CAMBRIDGE, Mass., January 22, 2026 – Insilico Medicine (“Insilico”, HKEX: 3696), a leading global AI-driven biotech company, today announced the launch of Science MMAI Gym, also branded as Insilico Medicine’s AI GYM for Science, a domain-specific training environment designed to transform ...

5 pre-conference symposia scheduled ahead of International Stroke Conference 2026

2026-01-22
DALLAS, Jan. 22, 2026 — The American Stroke Association, a division of the American Heart Association has expanded it’s International Stroke Conference with multiple pre-conference symposiums in 2026. The meeting is in New Orleans, Feb. 4-6, 2026, and is a world premier global event dedicated to advancing stroke and brain health science. The following is a list of all the pre-conference symposiums: State-of-the-Science Stroke Nursing Symposium Pre-Conference Symposium - Feb. 3, 2026; 8:00 a.m. to 5:00 p.m. CT This forum provides updates on nursing topics related to stroke care, including prevention, management, ...

LAST 30 PRESS RELEASES:

National Multiple Sclerosis Society awards Dr. Manuel A. Friese the 2025 Barancik Prize for Innovation in MS Research

PBM profits obscured by mergers and accounting practices, USC Schaeffer white paper shows

Breath carries clues to gut microbiome health

New study links altered cellular states to brain structure

Palaeontology: Ancient giant kangaroos could hop to it when they needed to

Decoded: How cancer cells protect themselves from the immune system

ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients

New study shows gut microbiota directly regulates intestinal stem cell aging

Leading cancer deaths in people younger than 50 years

Rural hospital bypass by patients with commercial health insurance

Jumping giants: Fossils show giant prehistoric kangaroos could still hop

Missing Medicare data alters hospital penalties, study finds

Experimental therapy targets cancer’s bodyguards, turning foe to friend to eliminate tumors

Discovery illuminates how inflammatory bowel disease promotes colorectal cancer

Quality and quantity? The clinical significance of myosteatosis in various liver diseases

Expert consensus on clinical applications of fecal microbiota transplantation for chronic liver disease (2025 edition)

Insilico Medicine to present three abstracts at the 2026 Crohn’s & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411, a novel gut-restricted PHD1/2 inhibitor fo

New imaging technology detects early signs of heart disease through the skin

Resurrected ancient enzyme offers new window into early Earth and the search for life beyond it

People with obesity may have a higher risk of dementia

Insilico Medicine launches science MMAI gym to train frontier LLMs into pharmaceutical-grade scientific engines

5 pre-conference symposia scheduled ahead of International Stroke Conference 2026

To explain or not? Need for AI transparency depends on user expectation

Global prevalence, temporal trends, and associated mortality of bacterial infections in patients with liver cirrhosis

Scientists discover why some Central Pacific El Niños die quickly while others linger for years

CNU research explains how boosting consumer trust unlocks the $4 billion market for retired EV batteries

Reimagining proprioception: when biology meets technology

Chungnam National University study finds climate adaptation can ease migration pressures in Africa

A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome

Brain network disorders study provides insights into the role of molecular chaperones in neurodegenerative diseases

[Press-News.org] Missing Medicare data alters hospital penalties, study finds
Hospitals in areas with high Medicare Advantage enrollment face inflated financial penalties for readmissions, because government uses only traditional Medicare data